文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

严重横纹肌溶解患者中细胞因子吸附器Cytosorb®对肌红蛋白的吸附与饱和动力学:一项前瞻性试验

Myoglobin adsorption and saturation kinetics of the cytokine adsorber Cytosorb® in patients with severe rhabdomyolysis: a prospective trial.
PubMed 文献 · Ann Intensive Care · 2024-06-22
一句话结论严重横纹肌溶解患者使用Cytosorb®吸附肌红蛋白,吸附能力约3小时后迅速下降,作者认为早期更换吸附器可能提高疗效。

前瞻性Cyto-SOLVE研究纳入20例重症监护室严重横纹肌溶解(血浆肌红蛋白>5000 ng/ml)、因急性肾损伤接受肾脏替代治疗并使用Cytosorb®清除肌红蛋白的患者。安装Cytosorb®后6小时血浆肌红蛋白中位数从56,894 ng/ml降至40,125 ng/ml(p<0.001),12小时后无显著变化;各时间点均可见显著体外吸附(p<0.05)。肌红蛋白相对变化和血浆清除率随时间迅速下降,10分钟时清除率中位数64.0 ml/min,12小时降至3.7 ml/min。作者认为吸附器能有效清除肌红蛋白,但约3小时后吸附能力迅速下降,严重横纹肌溶解患者早期更换吸附器可能提高疗效,临床获益需进一步临床试验验证。

要点

  • 20例严重横纹肌溶解(血浆肌红蛋白>5000 ng/ml)接受肾脏替代治疗并使用Cytosorb®的患者,安装后6小时血浆肌红蛋白中位数从56,894 ng/ml降至40,125 ng/ml(p<0.001)。
  • 安装Cytosorb®后12小时血浆肌红蛋白无显著变化。
  • 各时间点(10分钟、1、3、6、12小时)均可见显著体外肌红蛋白吸附(p<0.05)。
  • 肌红蛋白血浆清除率中位数从10分钟64.0 ml/min迅速降至1小时29.1 ml/min、3小时16.1 ml/min、6小时7.9 ml/min、12小时3.7 ml/min。
  • 作者认为严重横纹肌溶解患者早期更换吸附器可能提高疗效,临床获益需进一步临床试验验证。

适用人群与场景

  • 重症监护室严重横纹肌溶解患者,血浆肌红蛋白>5000 ng/ml,因急性肾损伤接受肾脏替代治疗,并使用Cytosorb®清除肌红蛋白(前瞻性Cyto-SOLVE研究纳入20例)。

诊断标准与关键阈值

  • 严重横纹肌溶解定义:血浆肌红蛋白>5000 ng/ml。

处置流程与药物剂量

  • 使用Cytosorb®(CS)进行体外肌红蛋白清除,在启动后10分钟、1、3、6、12小时测定血中及CS前、后肌红蛋白和肌酸激酶(CK)。
  • 作者认为严重横纹肌溶解患者早期更换吸附器可能提高疗效。

研究设计与关键结果

  • 前瞻性Cyto-SOLVE研究(NCT04913298)纳入20例重症监护室严重横纹肌溶解患者,血浆肌红蛋白>5000 ng/ml,因急性肾损伤接受肾脏替代治疗并使用Cytosorb®清除肌红蛋白。
  • 安装Cytosorb®后6小时血浆肌红蛋白中位数(IQR)从56,894 ng/ml(11,544; 102,737 ng/ml)降至40,125 ng/ml(7,879; 75,638 ng/ml)(p<0.001);12小时后无显著变化。
  • 各时间点(10分钟、1、3、6、12小时)均可见显著体外肌红蛋白吸附(p<0.05)。
  • 肌红蛋白相对变化中位数(IQR):10分钟-79.2%(-85.1; -47.1%),1小时-34.7%(-42.7; -18.4%),3小时-16.1%(-22.1; -9.4%),6小时-8.3%(-7.5; -1.3%),12小时-3.9%(-3.9; -1.3%)。
  • 肌红蛋白血浆清除率中位数(IQR):10分钟64.0 ml/min(58.6; 73.5 ml/min),1小时29.1 ml/min(26.5; 36.1 ml/min),3小时16.1 ml/min(11.9; 22.5 ml/min),6小时7.9 ml/min(5.5; 12.5 ml/min),12小时3.7 ml/min(2.4; 6.4 ml/min)。

证据类型、等级与局限

  • 证据类型:前瞻性试验(Cyto-SOLVE研究,NCT04913298,注册日期2021年5月7日)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为Cytosorb®吸附器能有效清除肌红蛋白,但吸附能力约3小时后迅速下降,导致有效性降低。
  • 作者认为严重横纹肌溶解患者早期更换吸附器可能提高疗效;临床获益需进一步临床试验验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Rhabdomyolysis is a serious condition that can lead to acute kidney injury with the need of renal replacement therapy (RRT). The cytokine adsorber Cytosorb® (CS) can be used for extracorporeal myoglobin elimination in patients with rhabdomyolysis. However, data on adsorption capacity and saturation kinetics are still missing.

METHODS: The prospective Cyto-SOLVE study (NCT04913298) included 20 intensive care unit patients with severe rhabdomyolysis (plasma myoglobin > 5000 ng/ml), RRT due to acute kidney injury and the use of CS for myoglobin elimination. Myoglobin and creatine kinase (CK) were measured in the patient´s blood and pre- and post-CS at defined time points (ten minutes, one, three, six, and twelve hours after initiation). We calculated Relative Change (RC, %) with: [Formula: see text]. Myoglobin plasma clearances (ml/min) were calculated with: [Formula: see text] RESULTS: There was a significant decrease of the myoglobin plasma concentration six hours after installation of CS (median (IQR) 56,894 ng/ml (11,544; 102,737 ng/ml) vs. 40,125 ng/ml (7879; 75,638 ng/ml) (p < 0.001). No significant change was observed after twelve hours. Significant extracorporeal adsorption of myoglobin can be seen at all time points (p < 0.05) (ten minutes, one, three, six, and twelve hours after initiation). The median (IQR) RC of myoglobin at the above-mentioned time points was - 79.2% (-85.1; -47.1%), -34.7% (-42.7;-18.4%), -16.1% (-22.1; -9.4%), -8.3% (-7.5; -1.3%), and - 3.9% (-3.9; -1.3%), respectively. The median myoglobin plasma clearance ten minutes after starting CS treatment was 64.0 ml/min (58.6; 73.5 ml/min), decreasing rapidly to 29.1 ml/min (26.5; 36.1 ml/min), 16.1 ml/min (11.9; 22.5 ml/min), 7.9 ml/min (5.5; 12.5 ml/min), and 3.7 ml/min (2.4; 6.4 ml/min) after one, three, six, and twelve hours, respectively.

CONCLUSION: The Cytosorb® adsorber effectively eliminates myoglobin. However, the adsorption capacity decreased rapidly after about three hours, resulting in reduced effectiveness. Early change of the adsorber in patients with severe rhabdomyolysis might increase the efficacy. The clinical benefit should be investigated in further clinical trials.

TRIAL REGISTRATION: ClinicalTrials.gov NCT04913298. Registered 07 May 2021, https//clinicaltrials.gov/study/NCT04913298.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Graf H, Gräfe C, Bruegel M, et al. Myoglobin adsorption and saturation kinetics of the cytokine adsorber Cytosorb® in patients with severe rhabdomyolysis: a prospective trial. Ann Intensive Care. 2024. PMID: 38907120. doi:10.1186/s13613-024-01334-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。